Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NCF1 | P14598 | 1/20 | 0.42 |
| ▸ | GNAO1 | P09471 | 3/20 | 0.37 |
| ▸ | GNAI3 | P08754 | 2/20 | 0.37 |
| ▸ | GNAI1 | P63096 | 2/20 | 0.37 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.36 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.35 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.35 |
| ▸ | CACNB1 | Q02641 | 1/20 | 0.35 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.35 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.33 |
| ▸ | ACHE | P22303 | 2/20 | 0.33 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.33 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.33 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.33 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.33 |
| ▸ | DRD2 | P14416 | 1/20 | 0.33 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.33 |
| ▸ | DRD4 | P21917 | 1/20 | 0.33 |
| ▸ | DRD3 | P35462 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26705170 | 0.86 | NCF1 (0.43) | NCF1GNAO1GNAI3GNAI1CACNA2D1 | |
| SCHEMBL24319799 | 0.84 | NCF1 (0.45) | NCF1GNAO1GNAI3GNAI1CACNA2D1 | |
| SCHEMBL123480 | 0.81 | NCF1 (0.54) | NCF1GNAO1GNAI3GNAI1SLC6A3 | |
| SCHEMBL12718190 | 0.80 | ACHE (0.39) | GNAO1CHRM5ACHEHRH3ADRA2C | |
| SCHEMBL26705215 | 0.80 | NCF1 (0.45) | NCF1GNAO1GNAI3GNAI1CACNA2D1 | |
| SCHEMBL12718174 | 0.80 | ACHE (0.39) | GNAO1CHRM5ACHEHRH3ADRA2C | |
| SCHEMBL255098 | 0.79 | — | — | |
| Fluoride SCHEMBL30330327 | 0.79 | NCF1 (0.52) | NCF1GNAO1GNAI3GNAI1SLC6A3 | |
| SCHEMBL23251417 | 0.79 | — | — | |
| SCHEMBL13479302 | 0.79 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230348427-A1 | COMPOUND FOR ANDROGEN RECEPTOR DEGRADATION, AND PHARMACEUTICAL USE THEREOF | UBIX THERAPEUTICS, INC. (KR) | 2023-11-02 | — | — | US | disclosed |
| US-20230348427-A1 | COMPOUND FOR ANDROGEN RECEPTOR DEGRADATION, AND PHARMACEUTICAL USE THEREOF | UBIX THERAPEUTICS, INC. (KR) | 2023-11-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230348427-A1 | COMPOUND FOR ANDROGEN RECEPTOR DEGRADATION, AND PHARMACEUTICAL USE THEREOF | AR, NR5A1, SHBG | NCF1 3023/4885GNAO1 1248/4885GNAI3 860/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.